Direct renin inhibition: From pharmacological innovation to novel therapeutic opportunities

High Blood Pressure and Cardiovascular Prevention

Volumn 18, Issue 3, 2011, Pages 93-105

  Volpe, Massimo ^a,b   Pontremoli, Roberto ^c   Borghi, Claudio ^d  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

ACE inhibitors; aliskiren; angiotensin receptor blockers; direct renin inhibition; hypertension

Indexed keywords

ALISKIREN; AMLODIPINE; ANGIOTENSIN I; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN HEXETIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; PLACEBO; RAMIPRIL; RENIN INHIBITOR; VALSARTAN;

ADD ON THERAPY; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE MONITORING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; HEART FAILURE; HEART INJURY; HEART PROTECTION; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY DISEASE; KIDNEY INJURY; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; UNSPECIFIED SIDE EFFECT;

AMIDES; ANIMALS; ANTIHYPERTENSIVE AGENTS; DIABETES MELLITUS; DIFFUSION OF INNOVATION; DRUG DESIGN; FUMARATES; HEART DISEASES; HUMANS; HYPERTENSION; KIDNEY DISEASES; RENIN; RENIN-ANGIOTENSIN SYSTEM; TRANSLATIONAL MEDICAL RESEARCH;

EID: 80053405422     PISSN: 11209879     EISSN: 11791985     Source Type: Journal    
DOI: 10.2165/11593540-000000000-00000     Document Type: Review

References (56)

1. Volpe M, Musumeci B, De Paolis P, et al. Angiotensin II AT2 receptor subtype: an uprising frontier in cardiovascular disease? J Hypertens 2003 Aug; 21 (8): 1429-43 (Pubitemid 36994116)
2. VolpeM,RuilopeLM,McInnesGT, et al.Angiotensin-II receptor blockers: benefits beyond blood pressure reduction? J Hum Hypertens 2005 May; 19 (5): 331-9 (Pubitemid 40662853)
3. Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008 May 17; 336 (7653): 1121-3 (Pubitemid 351731743)
4. Turnbull F, Woodward M, Neal B, et al. Do men and women respond differently to blood pressure-lowering treatment? Results of prospectively designed overviews of randomized trials. EurHeart J 2008 Nov; 29 (21): 2669-80
5. Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomized trials. Lancet 2003 Nov 8; 362 (9395): 1527-35 (Pubitemid 37410190)
6. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med 2005 Jun 27; 165 (12): 1410-9 (Pubitemid 40973424)
7. Strippoli GF, Craig M, Deeks JJ, et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review. BMJ 2004 Oct 9; 329 (7470): 828-39
8. Kunz R, Friedrich C, Wolbers M, et al. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008 Jan 1; 148 (1): 30-48 (Pubitemid 351688350)
9. Volpe M, Tocci G, Sciarretta S, et al. Angiotensin II receptor blockers and myocardial infarction: an updated analysis of randomized clinical trials. J Hypertens 2009 May; 27 (5): 941-6
10. Sciarretta S, Palano F, Tocci G, et al. Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk. Arch Intern Med 2011; 171 (5): 384-94
11. Frampton JE, Curran MP. Aliskiren: a review of its use in the management of hypertension. Drugs 2007; 67 (12): 1767-92 (Pubitemid 47263181)
12. Uresin Y, Mehtar Bozkurt M, Sabirli S, et al. Aliskiren, the future of reninangiotensin systemblockade? ExpertRevCardiovasc Ther 2007 Sep; 5 (5): 835-49
13. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar 23; 359 (9311): 995-1003 (Pubitemid 34286536)
14. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001 Sep 20; 345 (12): 861-9
15. Parving HH, Lehnert H, Brochner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001 Sep 20; 345 (12): 870-8
16. Dickstein K, Kjekshus J. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 2002 Sep 7; 360 (9335): 752-60 (Pubitemid 35247704)
17. Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003 Nov 13; 349 (20): 1893-906 (Pubitemid 37409706)
18. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARMOverall programme. Lancet 2003 Sep 6; 362 (9386): 759-66 (Pubitemid 37093915)
19. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. NEngl JMed 2001 Dec 6; 345 (23): 1667-75 (Pubitemid 33126822)
20. KonstamMA, Neaton JD,Dickstein K, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet 2009 Nov 28; 374 (9704): 1840-8
21. Yusuf S. From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. Am J Cardiol 2002 Jan 24; 89 (2A): 18A-25A
22. Muller DN, Luft FC. Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 2006 Mar; 1 (2): 221-8
23. Azizi M, Webb R, Nussberger J, et al. Renin inhibitionwith aliskiren: where are we now, and where are we going? J Hypertens 2006 Feb; 24 (2): 243-56 (Pubitemid 43348229)
24. Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007 Jan; 25 (1): 217-26 (Pubitemid 44885684)
25. Drummond W, Munger MA, Rafique Essop M, et al. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens (Greenwich) 2007 Oct; 9 (10): 742-50
26. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertensionmanagement: a European Society of Hypertension Task Force document. J Hypertens 2009 Nov; 27 (11): 2121-58
27. Palatini P, Jung W, Shlyakhto E, et al. Maintenance of blood-pressure-lowering effect following amissed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. JHumHypertens 2010Feb; 24 (2): 93-103
28. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.NEngl JMed 2000 Jan 20; 342 (3): 145-53 (Pubitemid 30051645)
29. Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008 Sep 27; 372 (9644): 1174-83
30. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008 Apr 10; 358 (15): 1547-59 (Pubitemid 351522739)
31. Bosch J, Lonn E, Pogue J, et al. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005 Aug 30; 112 (9): 1339-46 (Pubitemid 41266730)
32. Jong P, Yusuf S, Rousseau MF, et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a followup study. Lancet 2003 May 31; 361 (9372): 1843-8 (Pubitemid 36645177)
33. Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the direct rennin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009 Feb 3; 119 (4): 530-7
34. Parving HH, Persson F, Lewis JB, et al. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl JMed 2008 Jun 5; 358 (23): 2433-46 (Pubitemid 351793017)
35. McMurray JJ, Pitt B, Latini R, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008 May; 1 (1): 17-24
36. Volpe M. Cardiovascular risk in hypertension-can we ask for more? Focus on aliskiren. High Blood Press Cardiovasc Prev 2008; 15 (4): 255-68
37. Brunner HR, Laragh JH, Baer L, et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972; 286: 441-9
38. Alderman MH, Madhavan S, Ooi WL, et al. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324: 1098-104
39. AldermanMH, OoiWL, Cohen H, et al. Plasma renin activity: a risk factor for myocardial infarction in hypertensive patients. Am J Hypertens 1997; 10 (1): 1-8 (Pubitemid 27038966)
40. Francis GS, Cohn JN, Johnson G, et al. Plasma norepinephrine, plasma rennin activity, and congestive heart failure: relations to survival and the effects of therapy in V-HeFT II. The V-HeFT VA Cooperative Studies Group. Circulation. 1993; 87: VI40-48 (Pubitemid 23164221)
41. Latini R, Masson S, Anand I, et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J 2004; 25: 292-9 (Pubitemid 38295437)
42. Vantrimpont P, Rouleau JL, Wun CC, et al. Additive beneficial effects of betablockers to angiotensin-converting enzyme inhibitors in the Survival and Ventricular Enlargement (SAVE) Study. SAVE Investigators. J Am Coll Cardiol 1997 Feb; 29 (2): 229-36 (Pubitemid 27059948)
43. Muhlestein JB, May HT, Bair TL, et al. Relation of elevated plasma rennin activity at baseline to cardiac events in patients with angiographically proven coronary artery disease. Am J Cardiol 2010 Sep 15; 106 (6): 764-9
44. Frandsen E, Boomsma F, Persson F, et al. Measurement of bioactive rennin concentration and renin activity in the presence of exogenous renin substrate: effect of the oral direct renin inhibitor aliskiren. J Renin Angiotensin Aldosterone Syst 2008; 9 Suppl.: S12
45. Schmieder RE, Philipp T, Guerediaga J, et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 2009 Jan 27; 119 (3): 417-25
46. Persson F,Rossing P, SchjoedtKJ, et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 2008 Jun; 73 (12): 1419-25 (Pubitemid 351770494)
47. Persson F, Rossing P, Reinhard H, et al. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care 2009 Oct; 32 (10): 1873-9
48. Persson F, Lewis JB, Lewis EJ, et al. Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy. Diabetes Care 2010 Nov; 33 (11): 2304-9
49. Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009 May; 24 (5): 1663-71
50. Duprez DA, Munger MA, Botha J, et al. Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial. J Hum Hypertens 2010 Sep; 24 (9): 600-8
51. Lee HY, Oh BH. Cardio-renal protection with aliskiren, a direct renin inhibitor, in the ASPIRE HIGHER program. Expert Rev Cardiovasc Ther 2009 Mar; 7 (3): 251-7
52. Gheorghiade M, Albaghdadi M, Zannad F, et al. Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). Eur J Heart Fail 2011 Jan; 13 (1): 100-6
53. Krum H, Massie B, Abraham WT, et al. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patientswith chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. Eur J Heart Fail 2011 Jan; 13 (1): 107-14
54. Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC practice guidelines for themanagement of arterial hypertension. ESH-ESCTask Force on the Management of Arterial Hypertension. J Hypertens 2007 Sep; 25 (9): 1751-62 (Pubitemid 47356612)
55. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008 Oct; 29 (19): 2388-442
56. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009 Apr 14; 119 (14): 1977-2016